Chemotherapy-induced Anemia Market - Forecast(2025 - 2031)

Chemotherapy-induced Anemia Market Overview:

The Chemotherapy-induced Anemia Market size is estimated to reach $4.3 billion by 2030, growing at a CAGR of 7.1% during the forecast period 2024-2030. The chemotherapy-induced anemia market is a dynamic sector focused on creating effective treatments for managing anemia caused by cancer therapies, largely influenced by the rising incidence of cancer. As the rates of various cancers, such as breast and lung cancer, increase, so does the demand for chemotherapy, leading to a higher prevalence of anemia among patients. Innovations in treatment options, especially more effective erythropoiesis-stimulating agents (ESAs) and iron supplementation therapies, are improving patient outcomes and fueling market growth. Additionally, heightened awareness among healthcare providers and patients regarding the importance of addressing anemia in cancer care is leading to more proactive screening and intervention efforts. The expanding aging population, which is more vulnerable to both cancer and anemia, further drives the growth of this market.

The growing focus on personalized medicine is transforming the market by allowing healthcare providers to customize treatment strategies according to individual patient characteristics, such as genetic profiles and specific cancer types. This tailored approach significantly boosts treatment efficacy, as therapies can be fine-tuned to address the distinct needs of each patient. With ongoing advancements in biomarker research and diagnostic tools, the capacity to personalize treatment plans is anticipated to increase demand for targeted therapies. Moreover, the uptake of combination therapies is also on the rise. The effective integration of erythropoiesis-stimulating agents with iron supplementation addresses the complex causes of anemia, especially in patients receiving chemotherapy. This holistic approach not only enhances red blood cell production but also improves iron utilization, resulting in better overall patient outcomes. As clinical guidelines increasingly endorse combination treatments, healthcare providers are more inclined to adopt these strategies, ultimately boosting patient adherence and satisfaction.

Market Snapshot: 

Chemotherapy-induced Anemia Market- Report Coverage:

The “Chemotherapy-induced Anemia Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Chemotherapy-induced Anemia Market.

COVID-19 / Ukraine Crisis - Impact Analysis:  

During the Covid -19 pandemic, many elective procedures and routine chemotherapy sessions were postponed or cancelled, causing delays in cancer diagnoses and treatments, which subsequently affected the incidence of chemotherapy-induced anemia. However, the rise of telehealth services enabled healthcare providers to continue monitoring and managing patients remotely, emphasizing the importance of supportive care for managing anemia through virtual consultations and home-based care. Additionally, supply chain disruptions impacted the availability of certain anemia treatments, resulting in temporary shortages that affected patient regimens.

Russia- Ukraine conflict has severely strained healthcare infrastructure, with hospitals facing resource shortages and destruction, leading to delays in cancer care and inadequate management of chemotherapy-induced anemia. Furthermore, the conflict has put immense strain on Ukraine's healthcare infrastructure, severely limiting access to cancer care and anemia management for patients within the country. Many healthcare facilities have been damaged or destroyed, leading to inadequate treatment options for those who require timely interventions. The geopolitical instability adds to global market volatility, affecting investor confidence and potentially reducing funding for drug development.

Key Takeaways:

• North America Leads the Market:

North America region held a major market share in 2023. North America, particularly the United States, faces a significant burden of cancer. An aging population and unhealthy lifestyle choices are contributing factors. The American Cancer Society released its Cancer Statistics 2023 report, which showed that in 2023 in the United States, there will be nearly 2 million new cases of cancer diagnosed. North America is a hub for major pharmaceutical companies and biotech firms that invest significantly in research and development. This commitment leads to the ongoing introduction of innovative treatments for chemotherapy-induced anemia, enhancing patient outcomes and broadening market options. The U.S. has one of the highest per capita healthcare expenditures globally, which facilitates extensive access to advanced therapies and technologies that improve the management of chemotherapy-related side effects, including anemia. Healthcare spending in the U.S. is expected to have increased by 7.5% in 2023, reaching $4.8 trillion, outpacing the projected annual GDP growth rate of 6.1%. In 2023, the estimated healthcare spending per person in the U.S. was approximately $14,423, rising to $15,074 in 2024. Additionally, ongoing investments in healthcare infrastructure, such as new treatment centers and improved technology for monitoring and managing anemia, further bolster market growth. 

•  Erythropoietin-stimulating agents (ESAs) Treatment is Leading the Market

Erythropoietin-stimulating agents (ESAs) captured over 7.1% of the market share in 2023. By enhancing red blood cell production, ESAs effectively address the common side effect of anemia in cancer therapies. Among the first ESAs approved, Epogen has been a cornerstone treatment for anemia, particularly for patients undergoing dialysis or chemotherapy, thanks to its proven efficacy and safety profile. As chemotherapy-related anemia becomes increasingly prevalent, the demand for these agents has soared. Innovations in drug formulations, especially the development of longer-acting ESAs, have greatly improved patient adherence by decreasing the frequency of required injections, making them more attractive to both patients and healthcare providers. Furthermore, investments by pharmaceutical companies are leading to new ESA formulations that enhance treatment options and outcomes, further solidifying their dominance in anemia management and emphasizing their critical role in oncology care. For instance, Vadadustat received approval for medical use in the European Union in April 2023 and in the United States in March 2024. Recent studies highlighting the effectiveness of ESAs in improving cancer patients' quality of life have resulted in new approvals and expanded indications, contributing to the growing market for these treatments. Notably, in October 2023, Genexine announced it had received the first market approval for a novel long-acting erythropoietin from the Indonesian Food and Drug Authority.

• Treatment Related Anemia is the Largest Segment 

Treatment Related Anemia accounted for the largest market share in 2023 due to the direct impact of chemotherapy drugs on bone marrow. Chemotherapy treatments often suppress the bone marrow's ability to produce red blood cells, leading to anemia in a significant number of cancer patients. This type of anemia is characterized by symptoms such as fatigue, weakness, and reduced quality of life, which necessitate prompt medical intervention. The prevalence of treatment-induced anemia has driven substantial demand for therapies such as erythropoiesis-stimulating agents (ESAs), blood transfusions, and iron supplements. With the rising global cancer burden and the increasing use of chemotherapy in treatment regimens, the segment continues to dominate the market. The growing awareness among healthcare providers and patients about the importance of managing anemia to improve treatment outcomes further contributes to this segment's sustained growth in the chemotherapy-induced anemia market.

•  Rising Geriatric Population to Drive the Market

As the population ages, the incidence of cancer rises, resulting in an increasing number of older adults receiving chemotherapy. The World Health Organization (WHO) projects that by 2050, the global population of individuals aged 60 and older will double from 12% to 22%, meaning one in six people worldwide will be over 65. This aging demographic often faces multiple health challenges, contributing to a higher prevalence of moderate to severe anemia. Older patients are particularly susceptible to anemia as a side effect of chemotherapy, especially since many already have underlying health conditions that can worsen the situation. Chemotherapy can impair the bone marrow's ability to produce red blood cells, further exacerbating anemia. given the age-related changes in bone marrow function and overall health, managing chemotherapy-induced anemia (CIA) is crucial for this population. Healthcare providers are increasingly prioritizing the management of chemotherapy-induced anemia and other side effects, driving innovations in treatment options and supportive care. This has led to more proactive screening, innovative treatment approaches, and the development of supportive therapies designed to alleviate anemia in elderly patients undergoing chemotherapy.

• Patient Compliance and Adherence Poses a Challenge 

The complexity of treatment regimens often involves multiple medications and intricate schedules, making it difficult for patients to follow their plans consistently. Additionally, the side effects of chemotherapy, such as fatigue, nausea, and anemia itself, can discourage adherence, as patients may struggle with the physical and emotional toll of their treatment. Psychological barriers, including anxiety and depression, further complicate the situation, impacting a patient's willingness to engage in their care. Moreover, a lack of understanding regarding the importance of adherence can lead to missed doses or discontinuation of therapy altogether. Access issues, such as transportation difficulties, financial constraints, and insufficient support systems, also hinder patients' ability to maintain their treatment schedules. In a May 2024 survey by the American Cancer Society, almost half of the cancer patients and survivors surveyed (49%) reported experiencing medical debt. Addressing these multifaceted factors is crucial for improving patient outcomes, as enhanced adherence can significantly boost the efficacy of treatments and overall quality of life for those affected by chemotherapy-induced anemia.

For More Details on This Report - Request for Sample

Key Market Players: 

Product/Service launches, approvals, patents and events, acquisitions, partnerships, and collaborations are key strategies adopted by players in the Chemotherapy-induced Anemia Market. The top 10 companies in this industry are listed below:
1.    Amgen Inc.
2.    Pfizer Inc
3.    3SBIO Inc.
4.    Astellas Pharma Inc.
5.    F. Hoffmann-La Roche Ltd.
6.    FibroGen, Inc.
7.    Ranbaxy Laboratories Ltd.
8.    Bristol-Myers Squibb Company
9.    Johnson & Johnson
10.    Vifor Pharma AG

Scope of the Report: 

For more Lifesciences and Healthcare Market reports, please click here